The Use of Stem Cells as a Potential Treatment Method for Selected Neurodegenerative Diseases: Review
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Stem cells have been the subject of research for years due to their enormous therapeutic potential. Most neurological diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) are incurable or very difficult to treat. Therefore new therapies are sought in which autologous stem cells are used. They are often the patient's only hope for recovery or slowing down the progress of the disease symptoms. The most important conclusions arise after analyzing the literature on the use of stem cells in neurodegenerative diseases. The effectiveness of MSC cell therapy has been confirmed in ALS and HD therapy. MSC cells slow down ALS progression and show early promising signs of efficacy. In HD, they reduced huntingtin (Htt) aggregation and stimulation of endogenous neurogenesis. MS therapy with hematopoietic stem cells (HSCs) inducted significant recalibration of pro-inflammatory and immunoregulatory components of the immune system. iPSC cells allow for accurate PD modeling. They are patient—specific and therefore minimize the risk of immune rejection and, in long-term observation, did not form any tumors in the brain. Extracellular vesicles derived from bone marrow mesenchymal stromal cells (BM-MSC-EVs) and Human adipose-derived stromal/stem cells (hASCs) cells are widely used to treat AD. Due to the reduction of Aβ42 deposits and increasing the survival of neurons, they improve memory and learning abilities. Despite many animal models and clinical trial studies, cell therapy still needs to be refined to increase its effectiveness in the human body. Graphical Abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021 · cited 1×
“Long-term depletion of B cells by targeting CD20 with monoclonal antibodies can attenuate disease progression in relapsing–remitting and primary progressive MS (Hauser et al. 2017; Montalban et al. 2017; Myhr et al. 2019; Schwarz and Schmitz 2023).”
BackgroundOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905 · cited 1×
“Long-term depletion of B cells by targeting CD20 with monoclonal antibodies can attenuate disease progression in relapsing–remitting and primary progressive MS (Hauser et al. 2017; Montalban et al. 2017; Myhr et al. 2019; Schwarz and Schmitz 2023).”
BackgroundAnalysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
International Multiple Sclerosis Genetics Consortium (IMSGC) (2013) · Nature Genetics · doi:10.1038/ng.2770 · Cited by 1,386
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969 · cited 1×
“Therefore, stem cells are increasingly important in treating MS (Hauser and Cree 2020).”
BackgroundRecent global trends in the prevalence and incidence of dementia, and survival with dementia
Prince, M., Ali, G.-C., Guerchet, M., Prina, A. M., Albanese, E., & Wu, Y.-T. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0188-8 · Cited by 876
Chiò, A., Logroscino, G., Traynor, B. J., Collins, J., Simeone, J. C., Goldstein, L. A., & White, L. A. (2013) · Neuroepidemiology · doi:10.1159/000351153 · Cited by 862 · cited 1×
“Globally, the mean age of ALS onset is 62 years (Hulisz 2018; Chio et al. 2013; Kiernan et al. 2011; Mehta et al. 2018).”
BackgroundAstrocytes from familial and sporadic ALS patients are toxic to motor neurons
Haidet-Phillips, A. M., Hester, M. E., Miranda, C. J., Meyer, K., Braun, L., Frakes, A., Song, S., Likhite, S., Murtha, M. J., Foust, K. D., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1957 · Cited by 782
Research works printed but not linked: 156
- Ager RR et al (2015) Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of alzheimer’s disease and neuronal loss. Hippocampus 25(7):813–826. https://doi.org/10.1002/hipo.22405 · DOI · Paper page
- Al-Gharaibeh A, Culver R, Stewart AN et al (2017) Induced pluripotent stem cell-derived neural stem cell transplantations reduced behavioral deficits and ameliorated neuropathological changes in YAC128 mouse model of Huntington’s disease. Front Neurosci 10(11):628. https://doi.org/10.3389/fnins.2017.00628 · DOI
- Ayala-Cuellar AP, Kang J-H et al (2019) Roles of mesenchymal stem cells in tissue regeneration and immunomodulation. Biomol Ther (Seoul). 27(1):25–33 · DOI · Paper page
- Barczewska M, Maksymowicz S, Zdolińska-Malinowska I et al (2020) Umbilical cord mesenchymal stem cells in amyotrophic lateral sclerosis: an original study. Stem Cell Rev Rep 16(5):922–932. https://doi.org/10.1007/s12015-020-10016-7 · DOI
- Barker RA, Mason SL, Harrower TP et al (2013) The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington’s disease. J Neurol Neurosurg Psychiatry 84(6):657–665 · DOI
- Bellingacci L, Mancini A, Gaetani L, Tozzi A, Parnetti L, Di Filippo M (2021) Synaptic dysfunction in multiple sclerosis: a red thread from inflammation to network disconnection. Int J Mol Sci 22:9753 · DOI
- Berry JD, Cudkowicz ME, Windebank AJ, Staff NP et al (2019) NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. Neurology 93(24):e2294–e2305 · DOI · Paper page
- Boika A, Aleinikava N, Chyzhyk V, Zafranskaya M, Nizheharodava D, Ponomarev V (2020) Mesenchymal stem cells in Parkinson’s disease: Motor and nonmotor symptoms in the early posttransplant period. Surg Neurol Int 11(11):380. https://doi.org/10.25259/SNI_233_2020 · DOI
- Bond AM, Berg DA, Lee S, Garcia-Epelboim AS, Adusumilli VS, Ming GL, Song H (2020) Differential timing and coordination of neurogenesis and astrogenesis in developing mouse hippocampal subregions. Brain Sci 10:909 · DOI
- Brown RH, Alhalabi A (2017) Amyotrophic lateral sclerosis. N Engl J Med 377(2):162–172 · DOI · Paper page
- Burkhardt MF, Martinez FJ, Wright S et al (2013) A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol Cell Neurosci 56:355–364 · DOI · Paper page
- Burt RK, Balabanov R, Burman J et al (2019) Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA 321(2):165–174. https://doi.org/10.1001/jama.2018.18743 · DOI · Paper page
- Byrne JA (2014) Developing neural stem cell-based treatments for neurodegenerative diseases. Stem Cell Res Ther 5:72 · DOI
- Cable J, Fuchs E, Weissman I, Jasper H, Glass D, Rando TA, Blau H, Debnath S, Oliva A, Park S, Passegué E, Kim C, Krasnow MA (2020) Adult stem cells and regenerative medicine - a symposium report. Ann N Y Acad Sci 1462(1):27–36 · DOI
- Camnasio S, Carri AD, Lombardo A, Grad I, Mariotti C, Castucci A et al (2012) The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington’s disease patients demonstrates mutation relate d enhanced lysosomal activity. Neurobiol Dis 46:41–51 · DOI · Paper page
- Carstens M, Haq I, Martinez-Cerrato J et al (2020) Sustained clinical improvement of Parkinson’s disease in two patients with facially-transplanted adipose-derived stromal vascular fraction cells. J ClinNeurosci 81:47–51. https://doi.org/10.1016/j.jocn.2020.09.001 · DOI
- Casarosa S, Bozzi Y, Conti L (2014) Neural stem cells: ready for therapeutic applications? Mol Cell Ther 2:31 · DOI
- Chang KA, Kim HJ, Joo Y et al (2014) The therapeutic effects of human adipose-derived stem cells in alzheimer’s disease mouse models. Neurodegener Dis 13:99–102 · DOI
- Chen WW, Blurton-Jones M (2012) Concise review: can stem cells be used to treat or model alzheimer’s disease? Stem Cells 30(12):2612–8. https://doi.org/10.1002/stem.1240 · DOI
- Chen WS, Xu PZ, Gottlob K et al (2001) Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 15:2203–2208 · DOI · Paper page
- Chiavellini P, Canatelli-Mallat M, Lehmann M et al (2022) Therapeutic potential of glial cell line-derived neurotrophic factor and cell reprogramming for hippocampal-related neurological disorders. Neural Regen Res 17(3):469–476. https://doi.org/10.4103/1673-5374.320966 · DOI
- Choi KA, Hong S (2017) Induced neural stem cells as a means of treatment in Huntington’s disease. Expert OpinBiol Ther 17(11):1333–1343
- Connor B (2018) Concise review: the use of stem cells for understanding and treating huntington’s disease. Stem Cells 36:146–160 · DOI
- Cook D, Genever P (2013) Regulation of mesenchymal stem cell differentiation. Adv Exp Med Biol 786:213–229 · DOI
- Correale J, Gaitán MI, Ysrraelit MC, Fiol MP (2017) Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain 140(3):527–546
- Coyle PK (2021) What can we learn from sex differences in MS? J Pers Med 11:1006 · DOI
- Cudkowicz ME, Lindborg SR, Goyal NA, et al. (2022) A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve. 65(3):291–302. doi: https://doi.org/10.1002/mus.27472. Epub 2022 Jan 5. Erratum in: Muscle Nerve. 2022 Oct;66(4):E26-E27 · DOI
- Danielyan L, Beer-Hammer S, Stolzing A et al (2014) Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of alzheimer’s and parkinson’s disease. Cell Transplant 23(Suppl 1):S123-139 · DOI · Paper page
- Dantuma E, Merchant S, Sugaya K (2010) Stem cells for the treatment of neurodegenerative diseases. Stem Cell ResTher 1:37
- Dey ND, Bombard MC, Roland BP, Davidson S, Lu M, Rossignol J, Sandstrom MI, Skeel RL, Lescaudron L, Dunbar GL (2010) Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease. Behav Brain Res 25;214(2):193–200 · DOI · Paper page
- Di Filippo M, Mancini A, Bellingacci L, Gaetani L, Mazzocchetti P, Zelante T, La Barbera L, De Luca A, Tantucci M, Tozzi A et al (2021) Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. Cell Rep 37:110094 · DOI
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315–317 · DOI · Paper page
- Doshmanziari M, Shirian S, Kouchakian MR, Moniri SF, Jangnoo S, Mohammadi N, Zafari F (2021) Mesenchymal stem cells act as stimulators of neurogenesis and synaptic function in a rat model of alzheimer’s disease. Heliyon 7(9):e07996. https://doi.org/10.1016/j.heliyon.2021.e07996 · DOI
- Drews K, Jozefczuk J, Prigione A, Adjaye J (2012) Human induced pluripotent stem cells–from mechanisms to clinical applications. J Mol Med (berl) 90(7):735–745 · DOI
- Dulak J (2020) Komórki macierzyste: zastosowania, perspektywy, nieporozumienia. Nauka 1:99–123 · DOI
- Elia CA, Tamborini M, Rasile M, Desiato G, Marchetti S, Swuec P, Mazzitelli S, Clemente F, Anselmo A, Matteoli M et al (2019) Intracerebral injection of extracellular vesicles from mesenchymal stem cells exerts reduced Aβ plaque burden in early stages of a preclinical model of alzheimer’s disease. Cells 8:1059 · DOI · Paper page
- Eskandari N, Boroujeni ME, Abdollahifar MA, Piryaei A, Khodagholi F, Mirbehbahani SH, Siroosi S, Moghaddam MH, Aliaghaei A, Sadeghi Y (2021) Transplantation of human dental pulp stem cells compensates for striatal atrophy and modulates neuro-inflammation in 3-nitropropionic acid rat model of Huntington’s disease. Neurosci Res 170:133–144 · DOI
- Farinazzo A, Angiari S, Turano et al (2018) Nanovesicles from adipose-derived mesenchymal stem cells inhibit T lymphocyte trafficking and ameliorate chronic experimental autoimmune encephalomyelitis. Sci Rep 8:7473 · DOI · Paper page
- Fassas A, Kimiskidis VK, Sakellari I et al (2011) Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 76(12):1066–1070 · DOI
- Feldman EL, Boulis NM, Hur J et al (2014) Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol 75(3):363–373 · DOI · Paper page
- Filadi R, Pizzo P (2019) Defective autophagy and Alzheimer’s disease: is calcium the key? Neural RegenRes 14:2081–2082 · DOI
- Filipi T, Hermanova Z, Tureckova J, Vanatko O, Anderova AM (2020) Glial cells-the strategic targets in amyotrophic lateral sclerosis treatment. J Clin Med 9:261 · DOI
- Fink KD, Rossignol J, Crane AT et al (2013) Transplantation of umbilical cord-derived mesenchymal stem cells into the striata of R6/2 mice: Behavioral and neuropathological analysis. Stem Cell Res Ther 4:130 · DOI
- Fink KD, Deng P, Torrest A, Stewart H, Pollock K, Gruenloh W et al (2015) Developing stem cell therapies for juvenile and adult –onset Huntington’s disease. Regen Med 10:623–646 · DOI · Paper page
- Finkel Z, Esteban F, Rodriguez B, Fu T, Ai X, Cai L (2021) Diversity of adult neural stem and progenitor cells in physiology and disease. Cells 10(8):2045 · DOI
- Frausin S, Viventi S, VergaFalzacappa L, Quattromani MJ, Leanza G, Tommasini A et al (2015) Wharton’s jelly derived mesenchymal stromal cells: biological properties, induction of neuronal phenotype and current applications in neurodegeneration research. Acta Histochem 117:329–338 · DOI
- Friedenstein AJ, Chailakhjan RK, Lalykina KS (1970) The development of fibroblast colonies in monolayer cultures of guineapig bone marrow and spleen cells. Cell Tissue Kinet 3:393–403
- Gbaguidi B, Guillemin F, Soudant M, Debouverie M, Mathey G, Epstein J (2022) Age-period-cohort analysis of the incidence of multiple sclerosis over twenty years in Lorraine France. Sci Rep 12:1001 · DOI
- Giacomelli E, Vahsen BF, Calder EL, Xu Y, Scaber J, Gray E, Dafinca R, Talbot K, Studer L (2022) Human stem cell models of neurodegeneration: From basic science of amyotrophic lateral sclerosis to clinical translation. Cell Stem Cell 29(1):11–35 · DOI
- Glass JD, Boulis NM, Johe K et al (2012) Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells 30(6):1144–1151 · DOI · Paper page
- Gójska A, Michal Nyka AW (2008) Stemcells in neurology. AktualnNeurol 8(1):39–48
- Guo W et al (2012) Isolation of multipotent neural stem or progenitor cells from both the dentate gyrus and subventricular zone of a single adult mouse. Nat Protoc 7(11):2005–2012. https://doi.org/10.1038/nprot.2012.123 · DOI · Paper page
- Guo X, Disatnik M-H, Monbureau M, Shamloo M, Mochly-Rosen D, Qi X (2013) Inhibition of mitochondrial fragmentation diminishes Huntington’s disease-associated neurodegeneration. J Clin Invest 123:5371–88 · DOI · Paper page
- Gurusamy N, Alsayari A, Rajasingh S, Rajasingh J (2018) Adult stem cells for regenerative therapy. Prog Mol Biol Transl Sci 160:1–22 · DOI
- Ha S, Ahn S, Kim S et al (2014) In vivo imaging of human adipose-derived stem cells in alzheimer’s disease animal model. J Biomed Opt 19:051206 · DOI
- Haji N, Mandolesi G, Gentile A, Sacchetti L, Fresegna D, Rossi S, Musella A, Sepman H, Motta C, Studer V et al (2012) TNF -α-mediated anxiety in a mouse model of multiple sclerosis. Exp Neurol 237:296–303. https://doi.org/10.1016/j.expneurol.2012.07.010 · DOI · Paper page
- Hallett PJ, Cooper O, Sadi D, Robertson H, Mendez I, Isacson O (2014) Long-term health of dopaminergic neuron transplants in Parkinson’s disease patients. Cell Rep 7(6):1755–61. https://doi.org/10.1016/j.celrep.2014.05.027 · DOI · Paper page
- Harris VK, Yan QJ, Vyshkina T, Sahabi S, Liu X, Sadiq SA (2012) Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J Neurol Sci 313:167–177 · DOI
- Harris VK, Stark JW, Yang S et al (2020) Mesenchymal stem cell-derived neural progenitors in progressive MS: Two-year follow-up of a phase I study. Neurol Neuroimmunol Neuroinflamm 8(1):e928. https://doi.org/10.1212/NXI.0000000000000928 · DOI
- Hass R, Kasper C, Böhm S, Jacobs R (2011) Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissuederived MSC. Cell Commun Signal 9:12 · DOI · Paper page
- Hayashi Y, Lin HT, Lee CC, Tsai KJ (2020) Effects of neural stem cell transplantation in Alzheimer’s disease models. J Biomed Sci 27(1):29. https://doi.org/10.1186/s12929-020-0622-x · DOI
- Hedayatpour A, Ragerdi I, Pasbakhsh P, Kafami L, Atlasi N, PirhajatiMahabadi V et al (2013) Promotion of remyelination by adipose mesenchymal stem cell transplantation in a cuprizone model of multiple sclerosis. Cell J 15:142–151
- Hermann A, Storch A (2013) Induced neural stem cells (iNSCs) in neurodegenerative diseases. J Neural Transm (vienna) 120(Suppl 1):S19–S25. https://doi.org/10.1007/s00702-013-1042-9 · DOI
- Hulisz D (2018) Amyotrophic lateral sclerosis: disease state overview. Am J Manag Care 24(15 Suppl):S320–S326
- Islam J, So KH, Kc E, Moon HC, Kim A, Hyun SH, Kim S, Park YS (2021) Transplantation of human embryonic stem cells alleviates motor dysfunction in AAV2-Htt171-82Q transfected rat model of Huntington’s disease. Stem Cell Res Ther 12(1):585 · DOI
- Je G, Keyhanian K, Ghasemi M (2021) Overview of stem cells therapy in amyotrophic lateral sclerosis. Neurol Res 43(8):616–632 · DOI
- Jiang Q, Huang K, Lu F et al (2022) Modifying strategies for SDF-1/CXCR4 interaction during mesenchymal stem cell transplantation. Gen Thorac Cardiovasc Surg 70(1):1–10. https://doi.org/10.1007/s11748-021-01696-0 · DOI · Paper page
- Justyna Kacperska M, Dominika Książek-Winiarek, Karol Jastrzębski, et al. (2013) The attempts to use stem cells in the therapy of selected disorders of the nervous system”, Aktualn Neurol. 13(2): 145–156
- Karussis D, Karageorgiou C, Vaknin-Dembinsky A (2010) Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 67(10):1187–119 · DOI · Paper page
- Kassis I, Grigoriadis N, Gowda-Kurkalli B, Mizrachi-Kol R, Ben-Hur T, Slavin S et al (2008) Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 65:753–761 · DOI · Paper page
- Kaufmann M, Evans H, Schaupp AL, Engler JB, Kaur G, Willing A, Kursawe N, Schubert C, Attfield KE, Fugger L et al (2021) Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis. Med 2:296-312.e8 · DOI · Paper page
- Kawaguchi A (2020) Neuronal delamination and outer radial glia generation in neocortical development. Front Cell Dev Biol 8:623573. https://doi.org/10.3389/fcell.2020.623573 · DOI
- Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D et al (2009) Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology 87(1):26–33. https://doi.org/10.1002/jnr.21817 · DOI
- Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D et al (2013) Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology 80:2022 · DOI
- Kim HJ, Cho KR, Jang H, Lee NK, Jung YH, Kim JP, Lee JI, Chang JW, Park S, Kim ST, Moon SW, Seo SW, Choi SJ, Na DL (2021a) Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial. Alzheimers Res Ther 13(1):154. https://doi.org/10.1186/s13195-021-00897-2 · DOI · Paper page
- Kim A, Lalonde K, Truesdell A, Gomes Welter P, Brocardo PS, Rosenstock TR, Gil-Mohapel J (2021b) New Avenues for the treatment of Huntington’s disease. Int J Mol Sci 22(16):8363 · DOI · Paper page
- Kim A, Lalonde K, Truesdell A et al (2021c) New avenues for the treatment of Huntington’s disease. Int J Mol Sci 22(16):8363. https://doi.org/10.3390/ijms22168363 · DOI · Paper page
- Knippenberg S, Rath KJ, Boselt S et al (2017) Intraspinal administration of human spinal cord-derived neural progenitor cells in the G93A-SOD1 mouse model of ALS delays symptom progression, prolongs survival and increases expression of endogenous neurotrophic factors. J Tissue Eng Regen Med 11(3):751–764 · DOI
- Kolagar TA, Farzaneh M, Nikkar N, Khoshnam SE (2020) Human pluripotent stem cells in neurodegenerative diseases: potentials, advances and limitations. Curr Stem Cell Res Ther 15(2):102–110 · DOI
- Kondo T, Funayama M, Tsukita K et al (2014) Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Rep 3(2):242–249 · DOI · Paper page
- Kopen GC, Prockop DJ, Phinney DG (1999) Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci USA 96:10711–10716 · DOI · Paper page
- Lee JP et al (2008) Neural stem cell transplantation in mouse brain. Curr Protoc Neurosci. https://doi.org/10.1002/0471142301.ns0310s42 · DOI
- Lee JH, Liu JW, Lin SZ et al (2018) Advances in patient-specific induced pluripotent stem cells shed light on drug discovery for amyotrophic lateral sclerosis. Cell Transplant 27(9):1301–1312 · DOI
- Lulu S, Graves J, Waubant E (2016) Menarche increases relapse risk in pediatric multiple sclerosis. Mult Scler J 22:193–200 · DOI
- Ma DK, Bonaguidi MA, Ming GL, Song H (2009) Adult neural stem cells in the mammalian central nervous system. Cell Res 19:672–82 · DOI · Paper page
- Machaliński B (2008) Non-embryonic stem cells and regeneration of the nervous system. Pol Przegl Neurol 4(1):15–19
- Madrazo I, Kopyov O, Ávila-Rodríguez MA et al (2019) Transplantation of human neural progenitor cells (NPC) into putamina of parkinsonian patients: a case series study, safety and efficacy four years after surgery. Cell Transplant 28(3):269–285. https://doi.org/10.1177/0963689718820271 · DOI
- Martinez-Morales PL et al (2013) Progress in stem cell therapy for major human neurological disorders. Stem Cell Rev 9(5):685–699. https://doi.org/10.1007/s12015-013-9443-6 · DOI
- Mass RF, Vigne S, Pot C (2019) Resolution of inflammation during multiple sclerosis. Semin Immunopathol 41:711–726. https://doi.org/10.1007/s00281-019-00765-0 · DOI · Paper page
- Massirer KB et al (2011) Maintenance and differentiation of neural stem cells. Wiley Interdiscip Rev Syst Biol Med 3(1):107–114. https://doi.org/10.1002/wsbm.100 · DOI
- Mattis VB, Tom C, Akimov S, Saeedian J, Østergaard ME, Southwell AL et al (2015) HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Hum Mol Genet 24:3257–71 · DOI · Paper page
- Mazini L, Rochette L, Amine M, Malka G (2019) Regenerative capacity of adipose derived stem cells (ADSCs), comparison with mesenchymal stem cells (MSCs). Int J Mol Sci 20(10):2523. https://doi.org/10.3390/ijms20102523.PMID:31121953;PMCID:PMC6566837 · DOI · Paper page
- Mazzini L, Gelati M, Profico DC et al (2015) Human neural stem cell transplantation in ALS: initial results from a phase I trial. J Transl Med 27(13):17 · DOI · Paper page
- McColgan P, Tabrizi SJ (2018) Huntington’s disease: a clinical review. Eur J Neurol 25(1):24–34. https://doi.org/10.1111/ene.13413 · DOI · Paper page
- McCoy MK, Martinez TN, Ruhn KA et al (2008) Autologous transplants of adipose-derived adult stromal (ADAS) cells afford dopaminergic neuroprotection in a model of parkinson’s disease. Exp Neurol 210:14–29 · DOI
- Mehta P, Kaye W, Raymond J et al (2018) Prevalence of amyotrophic lateral sclerosis —United States, 2014. MMWR Morb Mortal Wkly Rep 67(7):216–218 · DOI · Paper page
- Miura K, Okada Y, Aoi T et al (2009) Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 27(8):743–745 · DOI · Paper page
- Morizane A, Kikuchi T, Hayashi T et al (2017) MHC matching improves engraftment of iPSC-derived neurons in non-human primates. Nat Commun 8:385. https://doi.org/10.1038/s41467-017-00926-5 · DOI · Paper page
- Mross K, Jankowska M, Meller A, Machowska-Sempruch K, Nowacki P, Masztalewicz M, Pawlukowska W (2022) Sensory integration disorders in patients with multiple sclerosis. J Clin Med 11:5183. https://doi.org/10.3390/jcm11175183 · DOI
- Mu S, Wang J, Zhou G, Peng W, He Z, Zhao Z, Mo CP, Qu J, Zhang J (2014) Transplantation of induced pluripotent stem cells improves functional recovery in Huntington’s disease rat model. PLoS ONE 9:101185 · DOI
- Munter J, Shafarevich I, Liundup A et al (2020) Neuro-Cells therapy improves motor outcomes and suppresses inflammation during experimental syndrome of amyotrophic lateral sclerosis in mice. CNS Neurosci Ther 26(5):504–517 · DOI
- Muraro PA, Pasquini M, Atkins HL et al (2017a) Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol 74:459–469 · DOI · Paper page
- Muraro PA, Martin R, Mancardi GL et al (2017b) Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol 13:391–405 · DOI · Paper page
- Myhr KM, Torkildsen O, Lossius A, Bo L, Holmoy T (2019) B cell depletion in the treatment of multiple sclerosis. Expert Opin Biol Ther 19:261–271 · DOI
- Namzaric (2016) (memantine and donepezil hydrochlorides). Full Prescribing Information. Allergan USA Inc, Irvine
- Nizzardo M, Simone C, Rizzo F et al (2014) Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural stem cells effectively improves the phenotype of an amyotrophic lateral sclerosis model. Hum Mol Genet 23(2):342–354 · DOI
- Papoutsi M, Labuschagne I, Tabrizi SJ, Stout JC (2014) The cognitive burden in Huntington’s disease: pathology, phenotype, and mechanisms of compensation. MovDisord 29:673–683
- Park HJ, Lee PH, Bang OY et al (2008) Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson’s disease. J Neurochem 107:141–151 · DOI · Paper page
- Peng J, Zeng X (2011) The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases. Stem Cell ResTher 2:32
- Petrou P, Kassis I, Levin N, Paul F, Backner Y, Benoliel T, Oertel FC, Scheel M, Hallimi M, Yaghmour N, Hur TB, Ginzberg A, Levy Y, Abramsky O, Karussis D (2020) Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain 143(12):3574–3588 · DOI · Paper page
- Petrou P, Kassis I, Yaghmour NE, Ginzberg A, Karussis D (2021) A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis. Front Biosci (landmark Ed) 26(10):693–706 · DOI
- Petrou P, Kassis I, Ginzberg A et al (2022) Effects of mesenchymal stem cell transplantation on cerebrospinal fluid biomarkers in progressive multiple sclerosis. Stem Cells Transl Med 11(1):55–58. https://doi.org/10.1093/stcltm/szab017.PMID:35641166;PMCID:PMC8895488 · DOI
- Phinney DG, Prockop DJ (2007) Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views. Stem Cells 25(11):2896-902. · DOI · Paper page
- Popescu IR, Nicaise C, Liu S et al (2013) Neural progenitors derived from human induced pluripotent stem cells survive and differentiate upon transplantation into a rat model of amyotrophic lateral sclerosis. Stem Cells Transl Med 2(3):167–174 · DOI
- Quarrell O, O’Donovan KL, Bandmann O, Strong M (2012) The prevalence of juvenile Huntington’s disease: A review of the literature and meta-analysis. PLoSCurr. https://doi.org/10.1371/4f8606b742ef3 · DOI
- Raymond J et al (2018) Prevalence of amyotrophic lateral sclerosis—United States, 2014. MMWR Morb Mortal Wkly Rep 67(7):216–218 · DOI · Paper page
- Reidling JC, Relaño-Ginés A, Holley SM et al (2018) Human neural stem cell transplantation rescues functional deficits in R6/2 and Q140 Huntington’s disease mice. Stem Cell Rep 10:58–72 · DOI
- Rice CM, Halfpenny CA, Scolding NJ (2003) Stem cells for the treatment of neurological disease. Transfus Med 13:351–361 · DOI
- Ring KL, An MC, Zhang N, O’Brien RN, Ramos EM, Gao F et al (2015) Genomic analysis reveals disruption of striatal neuronal development and therapeutic targets in human Huntington’s disease neural ste m cells. Stem Cell Rep 5:1023–1038 · DOI
- Riordan NH, Morales I, Fernández G, Allen N, Fearnot NE, Leckrone ME, Markovich DJ, Mansfield D, Avila D, Patel AN, Kesari S, Paz RJ (2018) Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med 16(1):57 · DOI · Paper page
- Schwarz K, Schmitz F (2023) Synapse dysfunctions in multiple sclerosis. Int J Mol Sci 24(2):1639. https://doi.org/10.3390/ijms24021639 · DOI
- Shahbazi E et al (2018) Reprogramming of somatic cells to induced neural stem cells. Methods 133:21–28. https://doi.org/10.1016/j.ymeth.2017.09.007 · DOI
- Shevchenko JL, Kuznetsov AN, Ionova TI et al (2012) Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol 40(11):892–898 · DOI
- Sinenko SA, Ponomartsev SV, Tomilin AN (2020) Human artificial chromosomes for pluripotent stem cell - based tissue replacement therapy. Exp Cell Res. 389(1):111882 · DOI
- Siwek T, Jezierska-Woźniak K, Maksymowicz S et al (2020) Repeat administration of bone marrow-derived mesenchymal stem cells for treatment of amyotrophic lateral sclerosis. Med Sci Monit 26:e927484. https://doi.org/10.12659/MSM.927484 · doi:10.12659/msm.927484
- Soler R, Fullhase C et al (2012) Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease. J Urol 187:1491–1497 · DOI · Paper page
- Stoddard-Bennett T, Reijo Pera R (2019) Treatment of parkinson’s disease through, personalized medicine and induced pluripotent stem cells. Cells 8(1):26 · DOI · Paper page
- Teng YD, Benn SC, Kalkanis SN et al (2012) Multimodal actions of neural stem cells in a mouse model of ALS: a meta -analysis. Sci Transl Med 4(165):161ral164 · DOI
- Terashima T, Kojima H, Urabe H et al (2014) Stem cell factor-activated bone marrow ameliorates amyotrophic lateral sclerosis by promoting protective microglial migration. J Neurosci Res. 92(7):856–869 · DOI
- Terashima T, Kobashi S, Watanabe Y et al (2020) Enhancing the therapeutic efficacy of bone marrow-derived mononuclear cells with growth factor-expressing mesenchymal stem cells for ALS in mice. iScience 23(11):101764 · DOI
- Tousley A, Kegel-Gleason KB (2016) Induced pluripotent stem cells in huntington’s disease research: progress and opportunity. J Huntingtons Dis 5(2):99–131 · DOI
- Tsiftsoglou AS (2021) Erythropoietin (EPO) as a key regulator of erythropoiesis, bone remodeling and endothelial transdifferentiation of multipotent mesenchymal stem cells (MSCs): implications in regenerative medicine. Cells 10(8):2140. https://doi.org/10.3390/cells10082140 · DOI
- Tuazon JP, Castelli V, Lee JY, Desideri GB, Stuppia L, Cimini AM, Borlongan CV (2019) Neural stem cells. AdvExp. Med Biol 1201:79–91
- Tyzack G, Lakatos A, Patani R (2016) Human stem cell-derived astrocytes: specification and relevance for neurological disorders. Curr Stem Cell Rep 2:236–247 · DOI · Paper page
- Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L, Clanet M, Fernandez O, Marriot J, Muraro P, Nabavi SM, Oliveri RS, Radue E, RamoTello C, Schiavetti I, Sellner J, Sorensen PS, Sormani MP, Wuerfel JT, Freedman MS, MESEMS investigators (2021) Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurol 20(11):917–929 · DOI · Paper page
- Van der Meer LB, van Duijn E, Wolterbeek R, Tibben A (2012) Adverse childhood experiences of persons at risk for Huntington’s disease or BRCA1/2 hereditary breast/ovarian cancer. Clin Genet 81:18–23 · DOI
- Venkatesan A, Johnson RT (2014) Infections and multiple sclerosis. Handb Clin Neurol 122:151–171. https://doi.org/10.1016/B978-0-444-52001-2.00007-8 · DOI
- Visweswaran M, Hendrawan K, Massey JC et al (2022) (2022) Sustained immunotolerance in multiple sclerosis after stem cell transplant. Ann ClinTransl Neurol 9(2):206–220. https://doi.org/10.1002/acn3.51510 · DOI
- Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I et al (2020) Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS. Mult Scler J 26:1816–1821 · DOI · Paper page
- Watanabe Y, Kazuki Y, Kazuki K et al (2015) Use of a human artificial chromosome for delivering trophic factors in a rodent model of amyotrophic lateral sclerosis. Mol Ther Nucleic Acids 4(10):e253 · DOI
- Wen Y, Jin S (2014) Production of neural stem cells from human pluripotent stem cells. J Biotechnol 188:122–129. https://doi.org/10.1016/j.jbiotec.2014.07.453 · DOI
- Wenceslau CV, de Souza DM, Mambelli-Lisboa NC, Ynoue LH, Araldi RP, da Silva JM, Pagani E, Haddad MS, Kerkis I (2022) Restoration of BDNF, DARPP32, and D2R expression following intravenous infusion of human immature dental pulp stem cells in Huntington’s disease 3-NP rat model. Cells 11(10):1664 · DOI
- Wenceslau CV, Kerkis I, Pompeia C, Haddad MS (2017) Pluripotent stem cells to model and treat huntington’s disease. In: Nagehan Ersoy Tunali (Eds) Huntington’s disease—molecular pathogenesis and current models. InTech, Palm Beach · DOI
- Wilkins A (2017) Cerebellar dysfunction in multiple sclerosis. Front Neurol 8:312. https://doi.org/10.3389/fneur.2017.00312 · DOI
- Wu Y-Y, Chiu F-L, Yeh C-S et al (2019) Opportunities and challenges for the use of induced pluripotent stem cells in modeling neurodegenerative disease. OpenBiol 9:180177
- Xia M, Zhao T, Wang X et al (2021) Brain-derived neurotrophic factor and its applications through nanosystem delivery. Iran J Pharm Res 20(4):137–151. https://doi.org/10.22037/ijpr.2021.115705.15484 · DOI
- Xie C, Liu YQ, Guan YT, Zhang GX (2016) Induced stem cells as a novel multiple sclerosis therapy. Curr Stem Cell Res Ther 11(4):313–320 · DOI
- Xin H, Katakowski M, Wang M et al (2017) MicroRNA-17-92 cluster in exosomes enhance neuroplasticity and functional recovery after stroke in rats. Stroke 48:747–753 · DOI · Paper page
- Yamanaka S (2020) Pluripotent stem cell-based cell therapypromise and challenges. Cell Stem Cell 27(4):523–531. https://doi.org/10.1016/j.stem.2020.09.014 · DOI · Paper page
- Yan M, Sun M, Zhou Y et al (2013) Conversion of human umbilical cord mesenchymal stem cells in Wharton’s jelly to dopamine neurons mediated by the Lmx1a and neurturin in vitro: potential therapeutic application for Parkinson’s disease in a rhesus monkey model. PLoS ONE 8:e64000 · DOI
- Zakrzewski W, Dobrzyński M, Szymonowicz M et al (2019) Stem cells: past, present, and future. Stem Cell Res Ther 10:68 · DOI · Paper page
- Zhan Y, Zheng H et al (2017) A novel presenilin 1 mutation (F388L) identified in a Chinese family with early-onset Alzheimer’s disease. Neurobiol Aging 50:168e1-168e4 · DOI
- Zhang X, Du F, Yang D, Yu C, Huang X, Liu W et al (2010) Transplanted bone marrow stem cells relocate to infarct penumbra and co-express endogenous proliferative and immature neuronal markers in a mouse model of ischemic cerebral stroke. BMC Neurosci 11:138 · DOI
- Zhang K, Liu GH, Yi F et al (2014) Direct conversion of human fibroblasts into retinal pigment epithelium-like cells by defined factors. Protein Cell 5(1):48–58 · DOI
- Zhang W, Gu GJ, Zhang Q, Liu JH, Zhang B, Guo Y, Wang MY, Gong QY, Xu JR (2017) NSCs promote hippocampal neurogenesis, metabolic changes and synaptogenesis in APP/PS1 transgenic mice. Hippocampus 27(12):1250–1263. https://doi.org/10.1002/hipo.22794 · DOI
- Zhang F-Q, Jiang J-L, Zhang J-T et al (2020) Current status and future prospects of stem cell therapy in alzheimer’s disease’. Neural Regen Res 15(2):242–250 · DOI
Cited by
Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders
Cohen, J., Mathew, A., Dourvetakis, K. D., Sanchez-Guerrero, E., Pangeni, R. P., Gurusamy, N., Aenlle, K. K., Ravindran, G., Twahir, A., Isler, D., et al. (2024) · Cells · doi:10.3390/cells13060511 · Cited by 103
Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions
Choi, H. K., Chen, M., Goldston, L. L., & Lee, K.-B. (2024) · Nano Convergence · doi:10.1186/s40580-024-00426-5 · Cited by 26
An Overview of Multiple Sclerosis In Vitro Models
Czpakowska, J., Kałuża, M., Szpakowski, P., & Głąbiński, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147759 · Cited by 7
“Moreover, for the same reason, technical reproducibility is restricted [35].”
BackgroundInfluential
Metadata
- Authors
- Cecerska-Heryć, E., Pękała, M., Serwin, N., Gliźniewicz, M., Grygorcewicz, B., Michalczyk, A., Heryć, R., Budkowska, M., & Dołęgowska, B.
- Venue
- Cellular and Molecular Neurobiology
- Published
- 2023-04-07
- Volume
- 43
- Issue
- 6
- Pages
- 2643-2673
- ISSN
- 0272-4340 (ISSN-L)
- 1573-6830
- OpenAlex
- W4362693053
- Cited by
- 59
- References
- 28
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Use of Stem Cells as a Potential Treatment Method for Selected Neurodegenerative Diseases: Review. https://app.cochat.ai/papers/10.1007/s10571-023-01344-6
- The paper
- Cecerska-Heryć, E., Pękała, M., Serwin, N., Gliźniewicz, M., Grygorcewicz, B., Michalczyk, A., Heryć, R., Budkowska, M., & Dołęgowska, B. (2023). The Use of Stem Cells as a Potential Treatment Method for Selected Neurodegenerative Diseases: Review. Cellular and Molecular Neurobiology. https://doi.org/10.1007/s10571-023-01344-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.